HONG KONG, Dec. 30, 2025 /PRNewswire/ -- Insilico Medicine (3696.HK), a clinical-stage drug discove...
* Insilico Medicine has licensed TaiGen Biotechnology exclusive rights in the Greater China area ...
* AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, success...
CAMBRIDGE, Mass., June 10, 2025 /PRNewswire/ -- Insilico Medicine
* Phase IIa study results of Rentosertib were published simultaneously in NatureMedicine(IF = 58....
CAMBRIDGE, Mass., March 13, 2025 /PRNewswire/ -- Insilico Medicine("Insilico"), a clinical-stage ge...
* This is the second asset Menarini Group has inlicensed from Insilico Medicine which was discove...
* Two separate Phase I studies conducted in Australia and in China indicate that ISM5411 was gene...
* The study presents the journey of designing and optimizing novel gut-restricted PHD inhibitors ...
Highlights: * ISM001-055 was safe and well-tolerated with a favorable PK profile in IPF patien...
* ISM001-055 is a novel drug designed in-house using generative AI to target TNIK (Traf2- and NCK...
Announcing Sustainability Benchmarking Initiative and New Gen-AI Features of Pharma.AI Platform CA...
